Reference: DSHB3156 **A.B.E. - Technical Data Sheet**

Product: Selective Supplement for *Burkholderia cepacia* (BCSA)

Specification

Selective supplement for the isolation of *Burkholderia cepacia* in clinical, water, cosmetics and other samples.

Presentation

	Packaging Details	Shelf Life	Storage
10 Freeze dried vials Vial with: 3 ± 0.1 g	22±0.25 x 55±0.5 mm glass vials, tag labelled, White plastic cap - 10 vials per box.	49 months	2-25 ºC

Composition

Composition (g/vial):
Polymixin B Sulphate..... 300,000 IU
Gentamicin ..... 5.00 mg
Vancomycin.....1.25 mg.

Reconstitute the original freeze-dried vial by adding 1 vial with sterile distilled water..... 6 ml

Note: Each vial is sufficient to supplement 500 ml of medium Base for *Burkholderia cepacia spp.*

Description /Technique

Description:
BCSA selective supplement is added to *Burkholderia cepacia* Agar Base in order to obtain a complete medium suitable for the isolation of *Burkholderia cepacia* in clinical samples.
The detection of *Burkholderia cepacia* is important in water systems, particularly where the water is to be used for the preparation of pharmaceuticals and cosmetics. The organism is resistant to many commonly-used disinfectants. *Burkholderia cepacia* is an important opportunistic pathogen in urinary, abdominal, respiratory and other infections.

Technique:
Collect, dilute and prepare samples and volumes as required according to specifications, directives, official standard regulations and/or expected results.
Once solidified on a flat surface, spread the plate streaking methodology or by spiral method.
Reconstitute the vial with 6 ml of steril distilled water in aseptic conditions and add it to 500 ml of sterilized BCSA Agar base cooled to 50ºC.
Do not overheat once suplemented.
Once solidified on a flat surface, spread the plates by streaking methodology or by spiral method.
Incubate the plates right side up aerobically at 33-37ºC for 48-72h.
(Incubation times longer than those mentioned above or different incubation temperatures mey be required depending on the sample, on the specifications, etc.)
After incubation, enumerate all the colonies that have appeared onto the surface of the agar.
Each laboratory must evaluate the results according to their specifications.

Quality control

Physical/Chemical control

Color : White-Gray

Microbiological control

Reconstitute 1 vial as indicated in COMPOSITION; shake and dissolve completely

Add 1 vial to 500 ml of medium base. DO NOT HEAT once supplemented.

Analytical methodology according to ISO 11133:2014/A1:2018; A2:2020

Aerobiosis. Incubation at 30-35 ºC. Reading at 24-48 until 72 h

According to ISO 11133 & USP Pharmacopeia

Microorganism	Growth
Burkholderia cepacia ATCC® 25416	Good (≥50%) - Greenish–brown colonies with yellow halo
Burkholderia cepacia ATCC® 25608	Good (≥50%) - Greenish–brown colonies with yellow halo
Staphylococcus aureus ATCC® 6538, WDCM 00032	Inhibited
Ps. aeruginosa ATCC® 9027, WDCM 00026	Inhibited
Burkholderia cenocepacia ATCC® BAA-245	Good (≥50%). White colonies
Burkholderia multivorans ATCC® BAA-247	Good (≥50%). White colonies surrounded by red zone

Sterility control

Add 5ml of the sample to 100 ml of TSB and to 100 ml Thioglycollate.
Incubation 48 hours at 30-35 ºC and 48 hours at 20-25 ºC: NO GROWTH.
Check at 7 days after incubation in same conditions.

Bibliography

· COENYE, T., P. VANDAMME, J.R.W. Govan and J.J. LiPuma. 2001. Taxonomy and identification of the Burkholderia cepacia Complex. J. Clin. Microbiol. 39:10:3427-3436.
· ERAM, S.M., Q.B. NEJAD, G.R. Khatami, N. NAFISSI. 2004. Detection of Burkholderia cepacia Complex in Patients with cystic fibrosis. Tanaffos 3:9:47-52.
· GILLIGAN, P.H., P.A. GAGE, L.M. BRADSHAW, D.V. SCHIDLOW and LV DeCicco. 1985. Isolation medium for the recovery of Pseudomonas cepacia from respiratory Secretions of Patients with cystic fibrosis. J. Clin. Microbiol. 22:5-8.
· HENRY, d.Ä., M.E. CAMPBELL, J.J. LiPuma and D.P. SPEERT. 1997. Identification of Burkholderia cepacia Isolates from Patients with cystic fibrosis and use of a simple new selective medium. J. Clin. 35:3:614-619 Microbiol.
· HENRY, d.Ä., M.E. CAMPBELL, C. McGimpsey, A. CLARKE, L. Louden, J.L. BURNS, M.H. ROE, P. VANDAMME and D.P. SPEERT. 1999. Comparison of isolation media for recovery from Burkholderia cepacia Complex Respiratory Secretions of Patients with cystic fibrosis. J. Clin. Microbiol. 37:4:1004-1007
· ISLES, A., I. MACLUSKY, M. COREY, R. GOLD, C. Prober, P. FLEMING, and H. LEVISON. 1984. Pseudomonas cepacia in cystic fibrosis Infection: An Emerging problem. J. Pediatr. 104:206-210.
· MILLER, JJ, 1996.A guide to Specimen Management in Clinical Microbiology. ASM Press., Washington D.C.
· WELCH, DF, M.J. Muszynski, C.H: PAI, M.J. MARCON, M.M. Hribar, P.H. Gilligan, J.M. Matsen, P.G. Ahlin, B.C. ·HILMAN and SA CHARTRAND. 1987. Selective and differential medium for recovery from the Pseudomonas cepacia respiratory tracts of Patients with cystic fibrosis. J. Clin. Microbiol. 25:1730-1734.
· ISO Standard 11133:2014 Microbiology of food, animal feed and water. Preparation, production, storage, and performance testing of culture media.
· USP 42 - NF 37 1S (2019) Chapter <60> Microbiological examination of nonsterile products: Test for *Burkholderia cepacia complex*. USP Corp. Inc. Rockville. MD. USA.